Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 12:2:401-9.
doi: 10.2147/IJWH.S6162.

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing)

Devorah R Wieder  1 , Lynn Pattimakiel
Affiliations

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing)

Devorah R Wieder et al. Int J Womens Health. .

Abstract

The contraceptive vaginal ring is a novel contraceptive method that offers unique advantages. Intravaginal delivery of both estrogen and progesterone allows continuous release of medication, resulting in lower systemic levels. The use of long-term combined hormonal contraception enables improved cycle control compared with progesterone-only methods. The indications and usage of the NuvaRing(®) are described along with the efficacy, tolerability, and safety. Overall, the contraceptive vaginal ring appears to be very effective, with a favorable side-effect profile, and is highly acceptable to most patients.

Keywords: NuvaRing; contraceptive agents; contraceptive device; ethinyl estradiol; etonogestrel; hormonal contraception; vaginal contraception; vaginal ring.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The contraceptive vaginal ring is positioned high in the vargina.
See this image and copyright information in PMC

References

    1. Alexander NJ, Baker E, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril. 2004;82:1–12. - PubMed
    1. Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care. 2007;12:240–247. - PubMed
    1. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A. In vivo assessment of NuvaRing placement. Contraception. 2005;72:196–199. - PubMed
    1. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469–475. - PubMed
    1. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585–593. - PubMed